Enhanced antitumor effect of axitinib synergistic interaction with AG490 via VEGFR2/JAK2/STAT3 signaling mediated epithelial-mesenchymal transition in cervical cancer in vitro

1. Jemal A, Bray F, MM Center, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.10.3322/caac.20107Open DOISearch in Google Scholar

2. Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 2008; 34:603-13.10.1016/j.ctrv.2008.05.006Open DOISearch in Google Scholar

3. Sirica AE, Campbell DJ, Dumur CI. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2011; 27:276-84.10.1097/MOG.0b013e32834405c3Open DOISearch in Google Scholar

4. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172:973-81.10.1083/jcb.200601018Search in Google Scholar

5. Lee MY, Chou CY, Tang MJ, Shen MR. Epithelialmesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res. 2008; 14:4743-50.10.1158/1078-0432.CCR-08-0234Open DOISearch in Google Scholar

6. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7:131-42.10.1038/nrm1835Open DOISearch in Google Scholar

7. Quintas-Cardama AK, Vaddi P L, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115:3109-17.10.1182/blood-2009-04-214957Search in Google Scholar

8. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002; 8:945-54.Search in Google Scholar

9. Gamero AM, Young HA, Wiltrout RH. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell. 2004; 5:111-2.10.1016/S1535-6108(04)00028-5Open DOISearch in Google Scholar

10. Lee HJ, Seo NJ, Jeong SJ, Park Y, Jung DB, Koh W, et al. Oral administration of penta-O-galloyl-beta-Dglucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition. Carcinogenesis. 2011; 32:804-11.10.1093/carcin/bgr015310643021289371Open DOISearch in Google Scholar

11. Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, et al. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis. 2010; 31:2097-104.10.1093/carcin/bgq16720732905Open DOISearch in Google Scholar

12. Zhang X, Song Y, Wu Y, Dong Y, Lai L, Zhang J, et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/ STAT3 signaling in endothelial cell. Int J Cancer. 2011; 129:2502-11.10.1002/ijc.25909Open DOISearch in Google Scholar

13. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial-Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling Pathway. Mol Cancer Res. 2011; 9:1658-1667.10.1158/1541-7786.MCR-11-0271Search in Google Scholar

14. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelialmesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009; 28:2940-7.10.1038/onc.2009.180Open DOISearch in Google Scholar

15. Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, et al. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal. 2011; 23:2076-85.10.1016/j.cellsig.2011.08.002Open DOISearch in Google Scholar

16. Canu B, Fioravanti A, Orlandi P, Di Desidero T, Ali G, Fontanini G, et al. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia. 2011; 13:217-29.10.1593/neo.101334Open DOISearch in Google Scholar

17. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008; 14: 7272-83.10.1158/1078-0432.CCR-08-0652Search in Google Scholar

18. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renalcell cancer: a phase II study. Lancet Oncol. 2007; 8: 975-84.10.1016/S1470-2045(07)70285-1Open DOISearch in Google Scholar

19. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008; 26:4708-13.10.1200/JCO.2007.15.9566485920618541897Open DOISearch in Google Scholar

20. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009; 27: 3836-41.10.1200/JCO.2008.20.835519597027Open DOISearch in Google Scholar

21. Sharma SV, Abhyankar RE, Burgess J, Infante RC, Trowbridge J, Tarazi, et al. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol. 2010; 21:297-304.10.1093/annonc/mdp48919940012Open DOISearch in Google Scholar

22. Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, et al. Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. Clin Cancer Res. 2011; 17:7462-9.10.1158/1078-0432.CCR-11-0534Open DOISearch in Google Scholar

23. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008; 371:2101-8.10.1016/S0140-6736(08)60661-3Search in Google Scholar

24. Kanthamneni N, Chaudhary A, Wang J, Prabhu S. Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. Int J Oncol. 2010; 37:177-85.Search in Google Scholar

25. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, et al. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 2009; 69:5893-900.10.1158/0008-5472.CAN-09-0755272467419567671Open DOISearch in Google Scholar

26. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, et al. Jak inhibitor induces S phase cellcycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2007; 363:738-44.10.1016/j.bbrc.2007.09.04917904524Search in Google Scholar

27. Li H, Wang H, Wang F, Gu Q, Xu X. Snail involves in the transforming growth factor beta1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells. PLoS One. 2011; 6:e23322.10.1371/journal.pone.0023322315444421853110Open DOISearch in Google Scholar

28. Huang C, Yang G, Jiang T, Huang K, Cao J, Qiu Z. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 2010; 29:51.10.1186/1756-9966-29-51288397520482858Search in Google Scholar

29. Rossler J, Monnet Y, Farace F, Opolon P, Daudigeos- Dubus E, Bourredjem A, et al. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Int J Cancer. 2011; 128:2748-58.10.1002/ijc.2561120715103Open DOISearch in Google Scholar

30. Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther. 2008; 7:79-89.10.1158/1535-7163.MCT-07-0584239075418202011Open DOISearch in Google Scholar

31. Longatto-Filho A, Pinheiro C, Martinho O, Moreira MA, Ribeiro LF, Queiroz GS, et al. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer. 2009; 9:212.10.1186/1471-2407-9-212271111219563658Open DOISearch in Google Scholar

32. Pang X, Wu Y, Lu B, Chen J, Wang J, Yi Z, et al. (-)- Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signalingmediated angiogenesis. Mol Cancer Ther. 2011; 10: 795-805.10.1158/1535-7163.MCT-10-0936322741221372225Open DOISearch in Google Scholar

33. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010; 70:1951-9.10.1158/0008-5472.CAN-09-3201285413420160026Open DOISearch in Google Scholar

34. Ren Z, Schaefer TS. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem. 2002; 277:38486-93.10.1074/jbc.M11243820011940572Open DOISearch in Google Scholar

35. Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem. 2002; 277: 45680-7.10.1074/jbc.M20425520012244095Open DOISearch in Google Scholar

36. Xu Z, Jiang Y, Steed H, Davidge S, Fu Y. TGFbeta and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cells. Biochem Biophys Res Commun. 2010; 401:376-81.10.1016/j.bbrc.2010.09.05920854793Open DOISearch in Google Scholar

37. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, et al. Cross talk of signals between EGFR and IL-6R through JAK2/ STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer. 2009; 100:134-44.10.1038/sj.bjc.6604794263469119088723Open DOISearch in Google Scholar

38. Dang H, Ding W, Emerson D, Rountree CB. Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer. 2011; 11:396.10.1186/1471-2407-11-396318919221929801Open DOISearch in Google Scholar

39. Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L, et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res. 2008; 68:4221-8.10.1158/0008-5472.CAN-07-512318519681Open DOISearch in Google Scholar